Serum levels of anti-PF4 IgG after AZD1222 (ChAdOx1 nCoV-19) vaccination Dahkki Taylor S. Cohen, Elizabeth J. Kelly, Sven Nylander, Himanshu Bansal, Brett M. Jepson, Prakash Bhuyan, Magdalena E. Sobieszczyk, Ann R. Falsey

Viečča ollesdeavstta

Geographical distribution of TTS cases following AZD1222 (ChAdOx1 nCoV-19) vaccination Dahkki Karina Soboleva, Nirmal Kumar Shankar, Madhavi Yadavalli, Cátia Ferreira, Nadia Foskett, Kert Putsepp, Lisa Beth Ferstenberg, Magnus Nord, Hugo Gomes da Silva, Prakash Bhuyan

Viečča ollesdeavstta

A First-in-Human Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Neutralization Profile of Two Investigational Long-Acting Anti-SARS-CoV-2 Monoclonal Ant... Dahkki Norman Moullan, Josephat Asiago, Kathryn Stecco, Salah Hadi, Moetaz Albizem, Holly Tieu, Björn Hock, Craig Fenwick, Kai Lin, Thomas Lengsfeld, Lauren Poffenbarger, David Liu, Didier Trono, Giuseppe Pantaleo, Rajeev Venkayya, Prakash Bhuyan

Viečča ollesdeavstta

Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months Dahkki Magdalena E. Sobieszczyk, Jill Maaske, Ann R. Falsey, Stephanie Sproule, Merlin L. Robb, Robert W. Frenck Jr., Hong-Van Tieu, Kenneth H. Mayer, Lawrence Corey, Kathleen M. Neuzil, Tina Tong, Margaret Brewinski Isaacs, Holly Janes, Himanshu Bansal, Lindsay M. Edwards, Justin A. Green, Elizabeth J. Kelly, Kathryn Shoemaker, Therese Takas, Tom White, Prakash Bhuyan, Tonya Villafana, and Ian Hirsch, on behalf of the AstraZeneca AZD1222 Clinical Study Group

Viečča ollesdeavstta